Westlake, Tx., USA - March 24, 2010, Westlake, Tx., USA - MiddleBrook Pharmaceuticals announced that James H. Cavanaugh, Martin A. Vogelbaum and Harold R. Werner have resigned from the board of directors, effective immediately.
Article continues below
Mr. Cavanaugh, Ph.D. has been a director inception of the company and has been a Managing Director of HealthCare Ventures LLC since 1989. Dr. Cavanaugh served as President of SmithKine and French Laboratories U.S., Inc., from March 1985 to February 1989 and as President of SmithKline Clinical Laboratories from 1981 to 1985.
Dr. Cavanaugh was the President of Allergan International, a specialty eye care company. Prior to industry experience, Dr. Cavanaugh was Deputy Assistant to the President for Domestic Affairs and Deputy Chief of the White House Staff. Before his White House tour, he served as Deputy Assistant Secretary for Health and Scientific Affairs in the U.S. Department of Health, Education and Welfare and as Special Assistant to the Surgeon General of the U.S. Public Health Service.
Mr. Cavanaugh was a Founding Director of the Marine National Bank in Santa Ana, California. Dr. Cavanaugh holds a Doctorate and a Master's degree from the University of Iowa and a Bachelor of Science degree from Fairleigh Dickinson University.
In addition to serving on the board of directors of several privately held health care and biotechnology companies, Mr. Cavanaugh has previously served on the Board of Directors of the National Venture Capital Association, the Pharmaceutical Research and Manufacturers Association , Unihealth America, the Proprietary Association, the Board of Trustees of the National Center for Genome Research and Trustee Emeritus of the California College of Medicine.
Mr. Cavanaugh was non-executive Chairman of Shire Pharmaceuticals Group plc from 1999 to 2008. Dr. Cavanaugh currently serves as a member of the board of PharmAthene, Inc. and Verenium Corporation (Chairman).
Mr. Vogelbaum was appointed a director in April 2007. Mr. Vogelbaum has been a partner with Rho Ventures since 2005. Prior to joining Rho, he was a general partner of Apple Tree Partners, a life sciences venture capital firm.
Previously, Mr. Vogelbaum was a general partner of Oxford Bioscience Partners, which he joined in 1993. Mr. Vogelbaum currently serves on the Board of Directors of several privately-held companies. Mr. Vogelbaum received an A.B. in biology and history from Columbia University.
Mr. Werner has been a director since inception of the company. Mr. Werner is a co-founder and general partner of HealthCare Ventures, a venture capital fund specializing in the health care industry.
Mr. Werner has served as a director of more than 30 public and private companies. Prior to the formation of HealthCare Ventures in 1985, Mr. Werner was Director of New Ventures for Johnson & Johnson Development Corporation. Before joining Johnson & Johnson in 1980, Mr. Werner was senior vice president of Robert S. First, Inc. and was responsible for managing its European and, later, U.S. health care management consulting business.
Mr. Werner currently serves on the Board of Directors of TetraLogic Pharmaceuticals Corporation, InfaCare Pharmaceutical Corporation, DecImmune, Inc., Aciex, Inc., Oriel Therapeutics, Inc., Promedior, Inc., Xencor, Inc., and Stemgent, Inc. ■